Differential Impact of Two Risk Communications on Antipsychotic Prescribing to People with Dementia in Scotland: Segmented Regression Time Series Analysis 2001–2011
Open Access
- 17 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e68976
Abstract
Regulatory risk communications are an important method for disseminating drug safety information, but their impact varies. Two significant UK risk communications about antipsychotic use in older people with dementia were issued in 2004 and 2009. These varied considerably in their content and dissemination, allowing examination of their differential impact. Segmented regression time-series analysis 2001–2011 for people aged ≥65 years with dementia in 87 Scottish general practices, examining the impact of two pre-specified risk communications in 2004 and 2009 on antipsychotic and other psychotropic prescribing. The percentage of people with dementia prescribed an antipsychotic was 15.9% in quarter 1 2001 and was rising by an estimated 0.6%/quarter before the 2004 risk communication. The 2004 risk communication was sent directly to all prescribers, and specifically recommended review of all patients prescribed relevant drugs. It was associated with an immediate absolute reduction in antipsychotic prescribing of 5.9% (95% CI −6.6 to −5.2) and a change to a stable level of prescribing subsequently. The 2009 risk communication was disseminated in a limited circulation bulletin, and only specifically recommended avoiding initiation if possible. There was no immediate associated impact, but it was associated with a significant decline in prescribing subsequently which appeared driven by a decline in initiation, with the percentage prescribed an antipsychotic falling from 18.4% in Q1 2009 to 13.5% in Q1 2011. There was no widespread substitution of antipsychotics with other psychotropic drugs. The two risk communications were associated with reductions in antipsychotic use, in ways which were compatible with marked differences in their content and dissemination. Further research is needed to ensure that the content and dissemination of regulatory risk communications is optimal, and to track their impact on intended and unintended outcomes. Although rates are falling, antipsychotic prescribing in dementia in Scotland remains unacceptably high.Keywords
This publication has 19 references indexed in Scilit:
- Prescribing of Rosiglitazone and Pioglitazone Following Safety SignalsDrug Safety, 2012
- Antipsychotic Therapy and Short-term Serious Events in Older Adults With DementiaArchives of internal medicine (1960), 2008
- Utilization and Costs of Antipsychotic Agents: A Canadian Population-Based Study, 1996–2006Psychiatric Services, 2008
- Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adultsCanadian Medical Association Journal, 2008
- A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)PLOS Medicine, 2008
- Antipsychotic Drug Use and Mortality in Older Adults with DementiaAnnals of Internal Medicine, 2007
- Decline in Treatment of Pediatric Depression After FDA Advisory on Risk of Suicidality With SSRIsAmerican Journal of Psychiatry, 2007
- Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patientsCanadian Medical Association Journal, 2007
- Risk of Death With Atypical Antipsychotic Drug Treatment for DementiaJAMA, 2005
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy and Therapeutics, 2002